search
Back to results

Patient-Centred Innovations for Persons With Multimorbidity - Quebec (PACEinMM-QC)

Primary Purpose

Hypertension, Depression, Anxiety

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
DIMAC02
Sponsored by
Université de Sherbrooke
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

PATIENTS (Studies 2.1 & 2.2):

Inclusion Criteria:

  • 3+ Chronic Conditions
  • 18 to 80 years of age
  • Eligible for DIMAC02 intervention

Exclusion Criteria:

  • Unable to reasonably respond to questionnaires or provide informed consent (ie. cognitive impairment or language barrier)
  • Deemed by provider to be too fragile

CAREGIVERS (Study 2.1):

  • Close family member (wife/husband, parent, son/daughter, brother/sister) and/or caregiver to a patient that has received DIMAC02 intervention (first component)
  • Sharing time with the patient (before, during and after the intervention)
  • French speaking

DECISION-MAKERS (Study 2.1):

  • FMG Physician-Manager, FMG Coordinators, Decision-Makers/Managers
  • Involved/Familiar with DIMAC02 program

DIMAC02 INTERDISCIPLINARY team (Study 2.1):

  • Nurse, Nutritionist, Kinesiologist, Social Worker, Psychologist
  • Has delivered DIMAC02 intervention to at least one patient

REFERRAL PROFESSIONALS (Study 2.1):

- Family physician or nurse/nurse practitioner

Sites / Locations

  • Université de Sherbrooke
  • CIUSSS du Sageunay-Lac-Saint-Jean

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

No Intervention

No Intervention

Arm Label

Group A

Group B

Group C

Arm Description

Intervention group (n = 163) Intervention: Participates in DIMAC02 Program

Control group (n = 163)

Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.

Outcomes

Primary Outcome Measures

Evaluation of Intervention Effectiveness - Change in Self-Management outcomes
Health Education Impact Questionnaire (HeiQ). Score: Reliable improvement

Secondary Outcome Measures

Evaluation of Intervention Effectiveness - Change in Chronic Diseases
Multimorbidity/Chronic Disease (MM-21): Score: number of Chronic diseases
Evaluation of Intervention Effectiveness - Change in Health Status
Health Status (VR-12): Score: Physical Component Summary (PCS) and the Mental Component Summary (MCS)
Evaluation of Intervention Effectiveness - Change in Quality of Life
Quality of Life (EQ5D-5L): Score: mean
Evaluation of Intervention Effectiveness - Change in Psychological Well-being
Psychological Well-being (Kessler 6 Scale).Score: mean
Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours
Lifestyle/Health Behaviours Questionnaire. Score: mean
Evaluation of Intervention Effectiveness - Equity
Demographics
Evaluation of Intervention Effectiveness - Change in Transitions of Care
Patient Perception of Transitions of Care. Score: Mean
Evaluation of Intervention Effectiveness - Change in Self-Efficacy
Self-Efficacy for Managing Chronic Disease Scale (SEM-CD). Score: mean
Evaluation of Intervention Effectiveness - Change in Patient-Centredness
Patient Perception of Patient-Centredness (PPPC). Score: Mean

Full Information

First Posted
March 16, 2016
Last Updated
November 2, 2022
Sponsor
Université de Sherbrooke
Collaborators
Canadian Institutes of Health Research (CIHR), Western University, Canada, Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean
search

1. Study Identification

Unique Protocol Identification Number
NCT02789800
Brief Title
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
Acronym
PACEinMM-QC
Official Title
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
April 22, 2016 (Actual)
Primary Completion Date
November 1, 2022 (Actual)
Study Completion Date
November 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Université de Sherbrooke
Collaborators
Canadian Institutes of Health Research (CIHR), Western University, Canada, Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the patient in context; and realign the health care system from separate silos to coordinated collaborations in care. PACE in MM will propose multifaceted innovations in Chronic Disease Prevention and Management (CDPM) that will be grounded in current realities (i.e. Chronic Care Models including Self-Management Programs), that are linked to Primary Care (PC) reform efforts. The study will build on this firm foundation, will design and test promising innovations and will achieve transformation by creating structures to sustain relationships among researchers, decision-makers, practitioners, and patients. The Team will conduct inter-jurisdictional comparisons and is mainly a Quebec (QC) - Ontario (ON) collaboration with participation from 3 other provinces: British Columbia (BC); Manitoba (MB); and Nova Scotia (NS). The Team's objectives are: 1) to identify factors responsible for success or failure of current CDPM programs linked to the PC reform, by conducting a realist synthesis of their quantitative and qualitative evaluations; 2) to transform consenting CDPM programs identified in Objective 1, by aligning them to promising interventions on patient-centred care for multimorbidity patients, and to test these new innovations' in at least two jurisdictions and compare among jurisdictions; and 3) to foster the scaling-up of innovations informed by Objective 1 and tested/proven in Objective 2, and to conduct research on different approaches to scaling-up. This registration for Clinical Trials only pertains to Objective 2 of the study.
Detailed Description
A recent systematic review on the prevalence of Multimorbidity (MM) recommended a count of 3+ chronic diseases, with no focus on any single chronic disease in particular. This definition identifies a more vulnerable population with higher needs, lower income or poverty, poorer outcomes and challenging processes of care. It includes people with a wide array of complexity from the uncomplicated course of minimally interacting chronic diseases to the highly complex MM patients. MM is not only important due to the burden on patients, but because it accounts for high utilization. The definition represents a continuum of vulnerability in which there are many opportunities for prevention and management. Despite the high prevalence of MM, most research and health care is still based on a single disease paradigm which may not be appropriate as 45% of primary care patients have MM. A recent Cochrane systematic review on the impact of interventions for patients with MM has identified a paucity of studies internationally with mixed results, thus paving the way for the work of this Team. The most promising intervention, to date, was enhanced teamwork in a multifaceted intervention involving multiple professionals. Patient-Centred Partnerships between Patients and Providers: The definition of patient-centred partnerships is derived from Canadian policy reports: "collaboration between informed, respected patients and a healthcare team." There is an internationally accepted comprehensive operational definition with four components which will guide many aspects of the proposed research program: first, exploring the patients' diseases and the illness experience; second, understanding the whole person in context; third, finding common ground; and fourth, enhancing the patient-provider relationship. There is empirical evidence for the impact of patient-centred partnerships on better patient outcomes and lower costs. Systematic reviews of interventions indicated promising results for feasible practice-based interventions targeting both providers and patients. Canadian policy reports defined this second facet of patient-centredness, as "seamless coordination and integration of care." Transitions requiring coordination are a key feature of care for patients with MM. Coordination has been shown to positively impact: symptom relief; social functioning; hospital re-admission and related costs. Papers reviewed by this Team identified the most promising type of intervention to be structured delivery system re-design. STUDY #2.1 Qualitative Evaluation of the aligned Programs Purpose: The study will: assess how the transformed program performs; distinguish between components of the interventions; and identify contextual factors that may have influenced the content and effectiveness of the intervention. It will also examine the local barriers and facilitators as well as the transitions and coordination of care. Methods and design: The Team will conduct a qualitative evaluation of the transformed programs to explain how various contexts influence observed effects [1] including the context of the health care systems in each province. A recent example of this research approach in Canada is Best et al, 2012 [2]. Data will be obtained from interviews and written documents. In-depth interviews will be conducted among the four categories of stakeholders. This will include: a) decision-makers (n = 10); b) primary care physicians (n = 10); c) professionals doing the interventions (n = 10); and a d) purposive sample of patients with multimorbidity (n = 10) and their informal caregivers (n=10) [51]. The number of interviews are estimates and will be guided by the saturation of data [3]. Data collection: In-depth interviews, lasting 30 to 60 minutes will ensure complete and detailed participation. The data collection will be held during the second year of the transformed program. The interview guides will examine how the context variables influence the effects and the elements that could potentially inform the development of future interventions. All interviews will be audiotaped and transcribed verbatim. Additionally, written documents will be collected (program team meeting summaries, a sample of 10 medical records or research records at each participating site, a checklist describing the fidelity of the intervention, all documents produced specifically for the intervention) to provide an in-depth understanding of the various contexts in which the interventions occurred. Data analysis: The data will be analyzed using an iterative and interpretative approach [4]. The data from all participants will be examined through both independent and team analysis occurring in a concurrent manner to build and develop on the emerging themes. A coding template will be developed and edited as new themes emerge while others are reclassified or discarded. A data management software will be used to organize the coded data and identify exemplar quotes reflecting the central themes. All written documents will undergo a content analysis. The final step of the analysis will be the triangulation of the synthesis of the themes from the stakeholder participants and the content analysis of the documents.[3-4] STUDY #2.2: Evaluation of effects of the aligned Programs Setting: The same consenting participating sites as described in study 2.1. The methods presented below are for one setting and will be duplicated in the second setting. Patients are referred to receive the services of these programs by their providers. The intervention the investigators are testing here is the aligned programs. Patients referred to these programs are new patients and have never been exposed to the intervention. In addition to the main reason for referral to the program, the referral form will also include eligibility details for the evaluation, including diagnoses. Patient sample: Patients recruited for the study will be cognitively intact and literate and aged between 18 and 80 years of age. The upper limit of 80 years is to avoid recruiting patients at risk of being institutionalized or dependent during the follow-up. Patients will present at least three chronic conditions. Methods and Design: Patients agreeing to participate will complete questionnaires at baseline (T1) collecting the sociodemographic data and baseline measures, which will be used to document equivalence between groups (groups are defined below). Effectiveness of the aligned program will be assessed using three strategies. To measure short-term effects (4 months), a randomized controlled trial (RCT) design with a delayed intervention will be used [5]. Eligible patients will be randomized after consent to receive either the intervention within a short period of time (Group A) or 4 months later (Group B); self-reported mailed questionnaires will be completed at baseline (T1) for all patient participants, 4 months after the end of the intervention for group A (T2) and 4 months after baseline for control group B (T2). This will constitute the short-term measure of effectiveness of the intervention. Group B will then receive the intervention. To measure the mid-term effects (one year) on patient-reported outcomes, a before and after study is proposed combining groups A and B together. The patients will complete the same questionnaire 12 months after the end of the intervention (T3). To measure mid-term (T3) and long-term effects (T4 after 2 years) on health services utilization and cost, all patients (groups A and B) will provide consent to give access to their health administrative (HA) data. At baseline, a control Group C will be constituted using anonymized HA data. Patients will be matched for gender, age, region and main three diagnoses. The Team will build algorithms for matching every set of controls. Groups A and B together will be compared to this propensity matched control group C in a before-after study using administrative (HA) data. Variables and outcome measures: The variables fall into 5 categories: sociodemographic; PC context; main co-variables of interest; primary outcomes; secondary outcomes. Socio-demographic characteristics include gender, age, education, family income, marital status, occupation, housing and number of persons living under the same roof. Context variables refer to type of PC organization in which the intervention occurs (Family Medicine Group). The three main co-variables of interest are the Team's three innovations: self-reported multimorbidity (measured by the Disease Burden Morbidity Assessment [6]; patient-centred partnership (Patient Perception of Patient-Centredness Scale [7-9]); and Patient centered coordination (the Patient Perceptions of Transitions in care, adapted by the investigators from Coleman [10]). The two primary outcome measures are the Health Education Impact Questionnaire (HeiQ) that provides a broad profile of the potential impacts of patient education interventions [11] and the level of perceived disease-management self-efficacy using the 6-item Self-Efficacy for Managing Chronic Disease (SEM-CD) [12]. Secondary patient perceived outcomes will be the VR-12 as a measure of health status and the "EuroQoL group" instrument called "EQ5D" as a measure of Quality of Life [13]. The Kessler psychological distress scale K-6 will measure psychological distress [14]. The investigators will also use a questionnaire on health behaviors [15]. Finally, HA data will also be used as secondary outcomes to compare health care utilization and cost before and after the intervention. HA data will include emergency department visits, avoidable hospital admissions, readmissions, time to first primary care visit after emergency department visit and continuity of care. Data analysis: Investigators will first describe participants' baseline characteristics in each group and compare among groups. To evaluate short-term effect, Groups A and B will be compared on T2 scores with an analysis of co-variance (ANCOVA) adjusted for T1 scores [16]. To document mid-term effects, a before and after measures analysis of variance will be used to study the evolution of continuous variables collected 3 times [17]. Sub-analyses by gender will be performed. Health system costs in intervention and control groups will be evaluated by using amounts paid to providers based on provincial fee schedules and cost-weighted utilization of institutions including hospitals and long-term care. Utilization records obtained from HA data will be multiplied by applicable cost weights [18] The methods employed will model the individual patient-level costs incurred in the health system, using methods developed for costing using administrative data[19]. Incremental resources in the intervention group will be identified and costed using applicable time/resource inputs and relevant wage rates following guidelines for economic evaluation in health interventions [20].

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Depression, Anxiety, Musculoskeletal Pain, Arthritis, Rheumatoid Arthritis, Osteoporosis, Chronic Obstructive Pulmonary Disease (COPD), Asthma, Chronic Bronchitis, Cardiovascular Disease, Heart Failure, Stroke, Transient Ischemic Attacks, Ulcer, Gastroesophageal Reflux, Irritable Bowel, Crohn's Disease, Ulcerative Colitis, Diverticulosis, Chronic Hepatitis, Diabetes, Thyroid Disorder, Cancer, Kidney Disease, Urinary Tract Problem, Dementia, Alzheimer's Disease, Hyperlipidemia, HIV

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
284 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Active Comparator
Arm Description
Intervention group (n = 163) Intervention: Participates in DIMAC02 Program
Arm Title
Group B
Arm Type
No Intervention
Arm Description
Control group (n = 163)
Arm Title
Group C
Arm Type
No Intervention
Arm Description
Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
Intervention Type
Behavioral
Intervention Name(s)
DIMAC02
Intervention Description
Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
Primary Outcome Measure Information:
Title
Evaluation of Intervention Effectiveness - Change in Self-Management outcomes
Description
Health Education Impact Questionnaire (HeiQ). Score: Reliable improvement
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3
Secondary Outcome Measure Information:
Title
Evaluation of Intervention Effectiveness - Change in Chronic Diseases
Description
Multimorbidity/Chronic Disease (MM-21): Score: number of Chronic diseases
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3
Title
Evaluation of Intervention Effectiveness - Change in Health Status
Description
Health Status (VR-12): Score: Physical Component Summary (PCS) and the Mental Component Summary (MCS)
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3
Title
Evaluation of Intervention Effectiveness - Change in Quality of Life
Description
Quality of Life (EQ5D-5L): Score: mean
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3
Title
Evaluation of Intervention Effectiveness - Change in Psychological Well-being
Description
Psychological Well-being (Kessler 6 Scale).Score: mean
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3
Title
Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours
Description
Lifestyle/Health Behaviours Questionnaire. Score: mean
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3
Title
Evaluation of Intervention Effectiveness - Equity
Time Frame
T1: Baseline
Title
Demographics
Time Frame
T1: Baseline
Title
Evaluation of Intervention Effectiveness - Change in Transitions of Care
Description
Patient Perception of Transitions of Care. Score: Mean
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3
Title
Evaluation of Intervention Effectiveness - Change in Self-Efficacy
Description
Self-Efficacy for Managing Chronic Disease Scale (SEM-CD). Score: mean
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3
Title
Evaluation of Intervention Effectiveness - Change in Patient-Centredness
Description
Patient Perception of Patient-Centredness (PPPC). Score: Mean
Time Frame
T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one year after T3

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
PATIENTS (Studies 2.1 & 2.2): Inclusion Criteria: 3+ Chronic Conditions 18 to 80 years of age Eligible for DIMAC02 intervention Exclusion Criteria: Unable to reasonably respond to questionnaires or provide informed consent (ie. cognitive impairment or language barrier) Deemed by provider to be too fragile CAREGIVERS (Study 2.1): Close family member (wife/husband, parent, son/daughter, brother/sister) and/or caregiver to a patient that has received DIMAC02 intervention (first component) Sharing time with the patient (before, during and after the intervention) French speaking DECISION-MAKERS (Study 2.1): FMG Physician-Manager, FMG Coordinators, Decision-Makers/Managers Involved/Familiar with DIMAC02 program DIMAC02 INTERDISCIPLINARY team (Study 2.1): Nurse, Nutritionist, Kinesiologist, Social Worker, Psychologist Has delivered DIMAC02 intervention to at least one patient REFERRAL PROFESSIONALS (Study 2.1): - Family physician or nurse/nurse practitioner
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin Fortin, MD, M.Sc
Organizational Affiliation
Université de Sherbrooke
Official's Role
Principal Investigator
Facility Information:
Facility Name
Université de Sherbrooke
City
Chicoutimi
State/Province
Quebec
ZIP/Postal Code
G7H 5H6
Country
Canada
Facility Name
CIUSSS du Sageunay-Lac-Saint-Jean
City
Chicoutimi
State/Province
Quebec
ZIP/Postal Code
G7H 7K9
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22985277
Citation
Best A, Greenhalgh T, Lewis S, Saul JE, Carroll S, Bitz J. Large-system transformation in health care: a realist review. Milbank Q. 2012 Sep;90(3):421-56. doi: 10.1111/j.1468-0009.2012.00670.x.
Results Reference
background
Citation
Pawson R, Tilley N. Realistic evaluation. London: Sage, 1997
Results Reference
background
Citation
Patton MQ. Qualitative research & evaluation. 3rd ed. Thousand Oaks, CA: Sage Publication. 2002
Results Reference
background
Citation
Crabtree BF, Miller WL. Doing Qualitative Research. Thousand Oaks, CA: Sage Publications Inc. 1999.
Results Reference
background
PubMed Identifier
20346624
Citation
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010 Aug;63(8):e1-37. doi: 10.1016/j.jclinepi.2010.03.004. Epub 2010 Mar 25. Erratum In: J Clin Epidemiol. 2012 Mar;65(3):351.
Results Reference
background
PubMed Identifier
22333434
Citation
Poitras ME, Fortin M, Hudon C, Haggerty J, Almirall J. Validation of the disease burden morbidity assessment by self-report in a French-speaking population. BMC Health Serv Res. 2012 Feb 14;12:35. doi: 10.1186/1472-6963-12-35.
Results Reference
background
PubMed Identifier
11032203
Citation
Stewart M, Brown JB, Donner A, McWhinney IR, Oates J, Weston WW, Jordan J. The impact of patient-centered care on outcomes. J Fam Pract. 2000 Sep;49(9):796-804.
Results Reference
background
PubMed Identifier
17893379
Citation
Stewart M, Brown JB, Hammerton J, Donner A, Gavin A, Holliday RL, Whelan T, Leslie K, Cohen I, Weston W, Freeman T. Improving communication between doctors and breast cancer patients. Ann Fam Med. 2007 Sep-Oct;5(5):387-94. doi: 10.1370/afm.721.
Results Reference
background
Citation
Stewart M, et al., The patient perception of patient-centeredness questionnaire (PPPC). Working Paper Series #04-1, April 2004.
Results Reference
background
PubMed Identifier
15725981
Citation
Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for posthospital care from the patient's perspective: the care transitions measure. Med Care. 2005 Mar;43(3):246-55. doi: 10.1097/00005650-200503000-00007.
Results Reference
background
PubMed Identifier
17027221
Citation
Nolte S, Elsworth GR, Sinclair AJ, Osborne RH. The extent and breadth of benefits from participating in chronic disease self-management courses: a national patient-reported outcomes survey. Patient Educ Couns. 2007 Mar;65(3):351-60. doi: 10.1016/j.pec.2006.08.016. Epub 2006 Oct 5.
Results Reference
background
Citation
Sherer M., et al., The self-efficacy scale: Construction and validation. Psychological Reports. 51: p. 663-671,1982.
Results Reference
background
PubMed Identifier
16571199
Citation
Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care. 2006 Spring;22(2):235-41. doi: 10.1017/S0266462306051051.
Results Reference
background
PubMed Identifier
12578436
Citation
Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, Hiripi E, Howes MJ, Normand SL, Manderscheid RW, Walters EE, Zaslavsky AM. Screening for serious mental illness in the general population. Arch Gen Psychiatry. 2003 Feb;60(2):184-9. doi: 10.1001/archpsyc.60.2.184.
Results Reference
background
Citation
Centers for Disease Control and Prevention (CDC), Behavioral Risk Factor Surveillance System Survey Questionnaire. 2007, Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
Results Reference
background
PubMed Identifier
16895814
Citation
Van Breukelen GJ. ANCOVA versus change from baseline: more power in randomized studies, more bias in nonrandomized studies [corrected]. J Clin Epidemiol. 2006 Sep;59(9):920-5. doi: 10.1016/j.jclinepi.2006.02.007. Epub 2006 Jun 23. Erratum In: J Clin Epidemiol. 2006 Dec;59(12):1334.
Results Reference
background
Citation
Daniel, W.W., Biostatistics: A foundation for analysis in the health sciences. 9th ed. Hoboken. NJ: Wiley. 2009.
Results Reference
background
Citation
Canadian Institute for Health Information. Canadian Hospital Reporting Project (CHRP). 2012; https://secure.cihi.ca/free_products/HI2013_Jan30_EN.pdf . Accessed 2016 March 14.
Results Reference
background
Citation
Wodchis, WP, et al., Guidelines on Person-Level Costing Using Administrative Databases in Ontario. Toronto: Health System Performance Research Network, 2011.
Results Reference
background
Citation
Drummond, MF, et al., Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005.
Results Reference
background
PubMed Identifier
34561255
Citation
Ngangue P, Brown JB, Forgues C, Ag Ahmed MA, Nguyen TN, Sasseville M, Loignon C, Gallagher F, Stewart M, Fortin M. Evaluating the implementation of interdisciplinary patient-centred care intervention for people with multimorbidity in primary care: a qualitative study. BMJ Open. 2021 Sep 24;11(9):e046914. doi: 10.1136/bmjopen-2020-046914.
Results Reference
derived
PubMed Identifier
28487349
Citation
Stewart M, Fortin M; Patient-Centred Innovations for Persons with Multimorbidity Team*. Patient-Centred Innovations for Persons with Multimorbidity: funded evaluation protocol. CMAJ Open. 2017 May 9;5(2):E365-E372. doi: 10.9778/cmajo.20160097.
Results Reference
derived
Links:
URL
http://www.paceinmm.recherche.usherbrooke.ca/
Description
Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) Program Website

Learn more about this trial

Patient-Centred Innovations for Persons With Multimorbidity - Quebec

We'll reach out to this number within 24 hrs